Date Published:

Sep

Abstract:

SCLC is frequently associated with paraneoplastic syndromes, including dermatomyositis. Patients with malignancy-associated dermatomyositis express a specific autoantibody pattern usually positive for anti-transcription intermediary factor 1-γ (TIF1-γ), suggesting anti-TIF1-γ plays a role in development of malignancy-associated dermatomyositis. We present a case of a patient with SCLC, paraneoplastic dermatomyositis, positive anti-TIF1-γ, and a point mutation in TIF1-γ coding gene, with prominent clinical response to chemoradiation. We suggest that this point mutation is pathogenic, providing evidence for the development of paraneoplastic dermatomyositis through immune cross-reactivity.

Notes:

2666-3643Arnon, JohnathanElia, AnnaNevo, YuvalLossos, AlexanderNechushtan, HovavCase ReportsJTO Clin Res Rep. 2021 Aug 9;2(9):100217. doi: 10.1016/j.jtocrr.2021.100217. eCollection 2021 Sep.

PublMed